简要报告：奥西替尼治疗各种EGFR外显子19突变变体的晚期非小细胞肺癌的有效性。

IF 3.3 3区医学 Q2 ONCOLOGY

Clinical lung cancer Pub Date : 2025-03-21 DOI:10.1016/j.cllc.2025.03.008

Lih-Chyun Chang , Hsiang-Wei Hu , Min-Shu Hsieh , Shang-Gin Wu , Jin-Yuan Shih

{"title":"简要报告：奥西替尼治疗各种EGFR外显子19突变变体的晚期非小细胞肺癌的有效性。","authors":"Lih-Chyun Chang , Hsiang-Wei Hu , Min-Shu Hsieh , Shang-Gin Wu , Jin-Yuan Shih","doi":"10.1016/j.cllc.2025.03.008","DOIUrl":null,"url":null,"abstract":"<div><div><ul><li><span>•</span><span><div>No significant difference in progression-free survival and overall survival with osimertinib was observed between E746del (deletions starting at codon E746) and L747del (deletions starting at codon L747) mutations.</div></span></li><li><span>•</span><span><div><em>EGFR</em> exon 19 non-LRE deletions, which do not include the entire LRE fragment, may be linked to a poorer prognosis in patients receiving osimertinib treatment.</div></span></li><li><span>•</span><span><div>Rare <em>EGFR</em> exon 19 mutations demonstrated diverse responses to osimertinib.</div></span></li></ul></div></div>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":"26 5","pages":"Pages e353-e357.e2"},"PeriodicalIF":3.3000,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Brief Report: The Effectiveness of Osimertinib in Advanced Nonsmall Cell Lung Cancer Harboring Various EGFR Exon 19 Mutation Variants\",\"authors\":\"Lih-Chyun Chang , Hsiang-Wei Hu , Min-Shu Hsieh , Shang-Gin Wu , Jin-Yuan Shih\",\"doi\":\"10.1016/j.cllc.2025.03.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div><ul><li><span>•</span><span><div>No significant difference in progression-free survival and overall survival with osimertinib was observed between E746del (deletions starting at codon E746) and L747del (deletions starting at codon L747) mutations.</div></span></li><li><span>•</span><span><div><em>EGFR</em> exon 19 non-LRE deletions, which do not include the entire LRE fragment, may be linked to a poorer prognosis in patients receiving osimertinib treatment.</div></span></li><li><span>•</span><span><div>Rare <em>EGFR</em> exon 19 mutations demonstrated diverse responses to osimertinib.</div></span></li></ul></div></div>\",\"PeriodicalId\":10490,\"journal\":{\"name\":\"Clinical lung cancer\",\"volume\":\"26 5\",\"pages\":\"Pages e353-e357.e2\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-03-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical lung cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1525730425000543\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical lung cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1525730425000543","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

•在E746del（从密码子E746开始的缺失）和L747del（从密码子L747开始的缺失）突变之间，奥西替尼的无进展生存期和总生存期没有显著差异。•EGFR外显子19非LRE缺失，不包括整个LRE片段，可能与接受奥西替尼治疗的患者预后较差有关。•罕见的EGFR外显子19突变对奥西替尼表现出不同的反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Brief Report: The Effectiveness of Osimertinib in Advanced Nonsmall Cell Lung Cancer Harboring Various EGFR Exon 19 Mutation Variants

•
No significant difference in progression-free survival and overall survival with osimertinib was observed between E746del (deletions starting at codon E746) and L747del (deletions starting at codon L747) mutations.
•
EGFR exon 19 non-LRE deletions, which do not include the entire LRE fragment, may be linked to a poorer prognosis in patients receiving osimertinib treatment.
•
Rare EGFR exon 19 mutations demonstrated diverse responses to osimertinib.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical lung cancer 医学-肿瘤学

CiteScore

7.00

自引率

2.80%

发文量

159

审稿时长

24 days

期刊介绍： Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.